Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: Pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 13, Issue 2, 2010, Pages 151-157

  Cheung, Raymond ^a   Cheng, Tien Tsai ^b   Dong, Yi ^c   Lin, Hsiao Yi ^d   Lai, Kamchuen ^e,f   Lau, Chak sing ^e,f   Feng, Huang ^g   Parsons, Bruce ^a  

^a PFIZER INC   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f QUEEN MARY HOSPITAL   (Hong Kong)

^g CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cyclo oxygenase inhibitors; Gastrointestinal; NSAIDs; Ulcers

Indexed keywords

CELECOXIB; DICLOFENAC; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHINA; COMORBIDITY; COMPARATIVE STUDY; MIDDLE AGED; PEPTIC ULCER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHINA; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER; PYRAZOLES; SULFONAMIDES; YOUNG ADULT;

EID: 77953800162     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01463.x     Document Type: Article

References (18)

1. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999, 107(Suppl. 6A):S3-8.
2. Ofman JJ, MacLean CH, Straus WL. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol 2002, 29:804-12.
3. Huang J-Q, Sridhar S, Hunt RH. Role of H. pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
4. Shiokawa Y, Nobenaga T, Saitoh T, Asagi S, Ogawa A. Epidemiological study on upper digestive injuries by non-steroidal anti-inflammatory drugs. J Jpn Rheum Assoc 1991, 31:96-111.
5. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. J Orthop Sci 2007, 12:341-6.
6. Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-8.
7. Schnitzer TJ, Burmester GR, Mysler E. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364:665-74.
8. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006, 25(Suppl. 7):22-9.
9. Singh G, Fort JG, Goldstein JL. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006, 119:255-66.
10. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-15.
11. Chan FK, Chung SC, Suen BY. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-73.
12. Chan FK, Wong VW, Suen BY. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-6.
13. Hochberg M, Chang R, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502.
14. Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celocoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA 2000, 284:1247-55.
15. Lai K-C, Chu K-M, Hui W-M. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-8.
16. Chan FKL, Hung LCT, Suen BY. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized, double-blind trial. Gastroenterol 2004, 127:1038-43.
17. Scheiman JM, Yeomans ND, Talley NJ. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX 2 inhibitors. Am J Gastroenterol 2006, 101:701-10.
18. Graham DY. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 2009, 7:1147-50.